Head-to-head · WeighScore
Oak vs Trimrose
The verdict
Oak takes it — 75.9/100 to 55.2/100.
Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Oak | Trimrose |
|---|---|---|
| WeighScore | 75.9/100 | 55.2/100 |
| Grade | C | C |
| Scorecard rank | #42 | #446 |
| Semaglutide | From $119/mo | Not disclosed |
| Tirzepatide | From $185/mo | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #42 · C
Strengths
- Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
- One price across every dosage, so titrating up costs no more
- No membership or subscription fee, and free shipping
- All 50 states, offered in Spanish as well as English
Where it loses points
- Same-day approval with no video call means very little clinical contact before a prescription
- No published lab or monitoring programme
- Injection only, and no brand-name lane
- Sold as packages, so re-ordering is on you
Graded #446 · C
Strengths
- Free, no-cost, no-obligation online eligibility quiz before any commitment
- Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
- Fully online — assessment, provider review, and home delivery with ongoing support
Where it loses points
- Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
- Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
- The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
- Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.